Add to Calendar 5/19/2021 8:00:00 AM 5/19/2021 4:00:00 PM State of Possible Conference 2021
The State of Possible Conference celebrates how the life sciences make the impossible possible. As MassBio’s annual meeting, the State of Possible Conference taps today’s brightest minds for engaging conversations on the latest developments in our industry, key insights from the past year, and building a better future for patients around the world.
Join MassBio and more than 800 virtual attendees for a free, interactive day of networking, keynotes, panel discussions, and Possible Talks from some of the most inspiring voices in the industry.

Webinar, click "live-stream" button to view
Co-Founder & Managing Partner, Trekk Venture Partners
Vikas is a founder and Managing Partners of Trekk Venture Partners, an emerging biotech venture capital fund. He has been working in the biotech industry for 20 years, with a particular focus on corporate strategy, capital formation, corporate partnerships, and M&A for early stage therapeutics companies. Prior to co-founding Trekk, Vikas was Senior Vice President of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and Series A investor before ultimately joining full-time in 2019. Vikas led Pandion through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Prior to Pandion, Vikas worked as an investor at SR One. During his time at SR One, Vikas invested in and served on the boards of 19 early stage biotech companies including Morphic Therapeutics (NASDAQ: MORF), River Vision Development (acquired by Horizon), Nimbus Therapeutics (Tyk2 program acquired by Takeda), Turning Point (acquired by BMS), Spero Therapeutics (tebipenem pivoxil HBr acquired by GSK) and Pandion (acquired by Merck). River Vision and Horizon developed Tepezza (teprotumumab) a new standard of care in the treatment of Grave’s Orbitopathy and the first therapy ever approved for the indication. Previously, Vikas was a Consultant at McKinsey & Co’s Pharmaceutical practice in New Jersey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals. He is a member of the Kauffman Fellows Society (Class 17). Vikas earned an MBA in Health Care Management from the Wharton School of the University of Pennsylvania and a BA in Neurobiology from Harvard University. Vikas truly believes that partnerships can be critical to the successful development of new medicines. In his free time, he hosts an interview series on the Timmerman Report with biotech business development executives about the deals they have worked on and lessons learned. Vikas lives in Somerville with his wife (who also works in the biotech industry) and two daughters.

Brought to you by